Loading…
← CockpitCompetitor Analysis › 2157.HK Lepu Biopharma Co. Ltd. Class HOpen in the cockpit ↗

Lepu Biopharma Co. Ltd. Class H2157.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major
Momentum laggard 10
Mkt cap
$580M
US dollars, full cap
Free float
52%
of shares outstanding
$/day
$5.19M
20-day average traded
Fwd P/E
53.6×
forward earnings
ROIC−WACC
-5.6 pp
WACC 8.8%
Hurdle
n/a
no reverse DCF
Next earnings
133 days
31 Mar 2027
Close · HKDHK$2.58
1D-1.3%
1W-11.8%
1M-33.7%
3M-37.0%
6M-42.8%
YTD-48.2%
1Y-57.8%
ATR %8.2%
52w lowhigh61.3% off high

What Lepu Biopharma does

Employees: 710

Lepu Biopharma at a glance

Size Lepu Biopharma (2157.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $580M, the 708th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$2.58 on 18 Nov 2026.

Performance Over six months the shares fell 42.8%, against -23.4% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 3rd lowest of 21 in its peer set.

Growth Revenue grew 46.9% over the last twelve months (peer median -1.7%); the operating margin is 7.0% (peer median 4.7%).

Valuation It trades at 53.6× forward earnings against a peer median of 11.3× (2nd most expensive of 10).

Capital Return on invested capital runs 5.6 points below its cost of capital (8.8% WACC).

Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 762157.HK 58
Six months, rebased to 100: Lepu Biopharma against the median of its 20 peers (local-currency closes).

Lepu Biopharma financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$1.11BHK$1.01BHK$399MHK$249MHK$18.1M
Revenue growth—+154%+60%+1,275%—
Gross profitHK$919MHK$856MHK$244MHK$104M-HK$95.2M
EBITDAHK$187MHK$199M-HK$306M-HK$319M-HK$607M
Net incomeHK$272MHK$283M-HK$446M-HK$24.4M-HK$801M
Free cash flow-HK$292M-HK$92.2M-HK$278M-HK$340M-HK$711M
Capital expenditureHK$266MHK$129MHK$66.9MHK$45.5MHK$134M
Total debtn/aHK$1.18BHK$894MHK$817MHK$767M

Quarterly statements and history in the cockpit →

Lepu Biopharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-30%-20%-10%-20%0%474322563613603439CGEMALMS300147ENTXIMMX688356600568600976301096002393300233DBV003850ZVRA45592157.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Lepu Biopharma is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%+75%20×40×3613603439688356600976301096002393003850ZVRA45592157.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Lepu Biopharma is the large dot.

Lepu Biopharma competitors and peer comparison

How Lepu Biopharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Lepu Biopharma against its 20 peers (data as of 18 Nov 2026)
Measure2157.HKPeer medianRank in peer set
1-month return-33.7%-11.1%3rd lowest of 21
6-month return-42.8%-23.4%3rd lowest of 21
Distance from 52-week high-61.3%-43.4%2nd lowest of 21
Revenue growth (TTM)+46.9%-1.7%3rd highest of 18
Operating margin7.0%4.7%6th highest of 17
Forward P/E53.6×11.3×2nd most expensive of 10
ROIC minus cost of capital-5.6 pp-2.7 pp7th lowest of 15
EV / EBITDA26.7×6.2×most expensive of 5
Net debt / EBITDA2.4×-1.8×most indebted of 5

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Lepu Biopharma 2157.HKHong Kong$580M-43%+47%7%53.6×n/an/a
Oneness Biotech 4743.TWOTaiwan$580M-13%+19%-589%n/an/an/a
Abbisko Cayman 2256.HKHong Kong$578M-39%-83%-520%n/an/an/a
Beijing Tong Ren Tang Chinese Medicine 3613.HKHong Kong$577M-26%-21%32%10.2×-15.4%+2.8%
GuiZhou SanLi Pharmaceutical 603439.SSChina$583M-20%-6%5%26.8×20.9%+21.9%
Cullinan Therapeutics CGEMUnited States$585M-37%n/an/an/an/an/a
Alumis ALMSUnited States$569M-80%-67%-5,375%n/an/an/a
Xiangxue Pharmaceutical 300147.SZChina$591M-41%+3%-39%n/a50.4%-12.3%
Entera Bio ENTXUnited States$568M+163%-100%n/an/an/an/a
Immix Biopharma IMMXUnited States$596M-20%n/an/an/an/an/a
Jenkem Technology 688356.SSChina$563M-30%+52%11%30.2×36.4%+11.2%
Zhong Zhu Healthcare 600568.SSChina$562M-22%-6%-34%n/an/an/a
JIANMIN PHARMACEUTICAL 600976.SSChina$598M-14%-2%8%6.7×-6.2%+6.5%
Hangzhou Bio-Sincerity Pharma-Tech 301096.SZChina$602M-38%+5%-30%54.0×n/an/a
Tianjin Lisheng Pharmaceutical 002393.SZChina$557M-24%-3%7%9.0×-5.8%+4.1%
Shandong Jincheng Pharmaceutical 300233.SZChina$604M-31%+2%4%n/a-0.6%-1.6%
DBV Technologies DBV.PAFrance$604M-46%n/an/an/an/an/a
Aclaris Therapeutics ACRSUnited States$555M-23%-59%-1,412%n/an/an/a
Boryung 003850.KSSouth Korea$554M-13%+6%6%11.3×-3.1%+12.6%
Zevra Therapeutics ZVRAUnited States$552M-9%+75%31%11.3×-4.9%+51.6%
Zeria Pharmaceutical 4559.TJapan$552M-12%+12%15%9.6×-12.3%+11.1%

Questions

Which companies are Lepu Biopharma's closest peers?
The cockpit's peer set: Oneness Biotech (4743.TWO), Abbisko Cayman (2256.HK), Beijing Tong Ren Tang Chinese Medicine (3613.HK), GuiZhou SanLi Pharmaceutical (603439.SS), Cullinan Therapeutics (CGEM), Alumis (ALMS), Xiangxue Pharmaceutical (300147.SZ), Entera Bio (ENTX).
Is Lepu Biopharma expensive compared with its peers?
On forward p/e it trades at 53.6× against a peer median of 11.3×, 2nd most expensive of 10 in its peer set.
How has Lepu Biopharma stock performed?
Over six months to 18 Nov 2026 the shares returned -42.8% against -23.4% for the median peer; over one year -57.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.